42 completed, 10 terminated, 4 unknown, 3 recruiting. 30 Phase 2, 10 Phase 1, 10 Phase 3, 8 Not applicable, 4 Phase 4.
Follow Lovastatin: new trials by email Literature Review of Lovastatin trials Research Report on Lovastatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-10-31 | 2026-09-22 |
| Comparing Inclisiran Versus Statin for Primary Aldosteronism inclisiran, Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin), Spironolactone (drug) - Primary Aldosteronism | Not applicable | Recruiting | Third Military Medical University | 50 | 2026-10-01 | 2026-10-21 |
| Evaluation Of The Efficacy Of Subgingival Application Of Lovastatin Gel As An Adjunct To Non-Surgical Treatment Of Periodontitis In Generally Healthy Smokers And Non-Smokers Patients in Central Europe. Subgingival application of 1.2% lovastatin, Subgingival application of placebo gel - Periodontal Diseases, Periodontitis | Not applicable | Recruiting | Medical University of Silesia | 44 | 2025-07-11 | 2026-02-20 |
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| Real World Evidence Study of Statin Use in Brazil Statin - Cardiovascular Diseases, Myocardial Infarction | Completed | Hospital Israelita Albert Einstein | 2133900 | 2021-11-19 | 2024-05-14 | |
| Lovastatin for Treatment of Brain Arteriovenous Malformations Lovastatin, Placebo - Cerebral Arteriovenous Malformation | Phase 2 | Unknown | Beijing Tiantan Hospital | 1244 | 2021-01-01 | 2020-03-09 |
| DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone Lovastatin 2%, 2% Cholesterol Cream, Lovastatin 2% Cream - Actinic Porokeratosis | Phase 1 | Completed | Medical University of South Carolina | 31 | 2020-08-24 | 2023-12-07 |
| The GABAergic Inhibitory System in Drug Resistant Epilepsy Lovastatin 60 MG, Placebo - Drug Resistant Epilepsy, Temporal Lobe Epilepsy | Not applicable | Completed | University of Coimbra | 5 | 2020-01-12 | 2025-01-23 |
| Synaptic Plasticity and Cognitive Function in RASopathies Lovastatin, Lamotrigine - Impaired Synaptic Plasticity, Impaired Cognition | Phase 2 | Terminated | Technical University of Munich | 16 | 2019-03-22 | 2023-11-30 |
| From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 Lovastatin 60 MG, Placebos - Autism Spectrum Disorder, Neurofibromatosis 1 | Not applicable | Completed | University of Coimbra | 16 | 2019-02-19 | 2021-04-02 |
| Efficacy and Safety of SYN-010 in IBS-C SYN-010 21 mg, SYN-010 42 mg, Placebo - Irritable Bowel Syndrome With Constipation | Phase 2 | Terminated | Cedars-Sinai Medical Center | 59 | 2018-12-24 | 2022-07-13 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia Alirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin - Hypercholesterolemia | Phase 3 | Completed | Sanofi | 18 | 2018-08-31 | 2020-12-29 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin - Hypercholesterolaemia | Phase 3 | Completed | Sanofi | 153 | 2018-05-31 | 2023-05-06 |
| Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Lovastatin in the Preservation of the Tooth Socket Lovastatin 40 MG, without drug with Bone graft - Bone Loss | Phase 2 | Unknown | Islamic Azad University, Sanandaj | 20 | 2018-02-22 | 2019-06-11 |
| Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease Lovastatin, Placebo - Parkinson Disease | Phase 2 | Unknown | National Taiwan University Hospital | 80 | 2017-05-15 | 2017-10-17 |
| Interventions for Reading Disabilities in NF1 Lovastatin, reading tutoring intervention, Placebo Oral Tablet - Neurofibromatosis Type 1, Learning Disability | Phase 2 | Active not recruiting | Vanderbilt University | 120 | 2016-11-01 | 2026-07-01 |
| Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome Minocycline, then Minocycline/Lovastatin, Lovastatin, then Minocycline/Lovastatin - Fragile X Syndrome | Phase 2 | Completed | Université de Sherbrooke | 22 | 2016-03-01 | 2018-10-15 |
| Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome Lovastatin, Placebo - Fragile X Syndrome, Genetic Diseases | Phase 4 | Completed | University of California, Davis | 30 | 2016-01-01 | 2019-09-11 |
| Neurophysiological and Acute Pharmacological Studies in FXS Patients Acamprosate, Lovastatin, Minocycline - Fragile X Syndrome | Early Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 29 | 2016-01-01 | 2021-11-26 |
| Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers XueZhiKang, Lovastatin - Lipid Metabolism Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 20 | 2015-11-01 | 2016-12-05 |
Showing 20 of 64. Sign in to see all of them.
Hypercholesterolemia (8) · Cardiovascular Diseases (7) · Neurofibromatosis 1 (5) · Atherosclerosis (4) · Breast Neoplasms (4) · Coronary Disease (4) · Heart Diseases (4) · Fragile X Syndrome (3) · Myocardial Ischemia (3) · Stroke (3) · Coronary Artery Disease (2) · Diabetes Mellitus (2) · Dyslipidemias (2) · Hyperlipidemias (2) · Hyperlipoproteinemia Type II (2)
National Heart, Lung, and Blood Institute (NHLBI) (3) · Canadian Network for Observational Drug Effect Studies, CNODES (2) · Columbia University (2) · Kos Pharmaceuticals (2) · Merck Sharp & Dohme LLC (2) · Mutual Pharmaceutical Company, Inc. (2) · National Taiwan University Hospital (2) · Sanofi (2) · University of Coimbra (2) · University of Iowa (2) · University of Washington (2) · Université de Sherbrooke (2) · Virginia Commonwealth University (2) · Washington University School of Medicine (2) · AB Biotics, SA (1)
United States (32) · Canada (9) · Taiwan (5) · Brazil (3) · Denmark (3) · Netherlands (3) · Poland (3) · China (2) · Czechia (2) · Italy (2) · Mexico (2) · Portugal (2) · Russia (2) · Slovenia (2) · Spain (2)
Colin Dormuth, M.Sc., Sc.D. (2) · Raymond Hohl, MD (2) · Aleksandra Djukic, MD PhD (1) · Ali Rezaie, MD MSc (1) · Amy S Paller, MD (1) · Andrew A Davis, MD (1) · B. Greg Brown, M.D., Ph.D (1) · Betty Diamond, MD (1) · Blanca Camoretti-Mercado, Ph.D. (1) · Carlos J Montoya, MD, PhD (1) · Carrie E Bearden, PhD (1) · Chin-Hsien Lin, MD, PhD (1) · Connie Davis, MD. (1)
PMID 23352857, PMID 19538732, PMID 19574441, PMID 19609078, PMID 20212073, PMID 23085245, PMID 23511950, PMID 23630244, PMID 24166281, PMID 24451612, PMID 24874977, PMID 27956565, PMID 31628482, PMID 32316911, PMID 35970940, PMID 36114762, PMID 36167501, PMID 36325897, PMID 36947042, PMID 37280688, PMID 37497398, PMID 37565307, PMID 38315470, PMID 38431498, PMID 39248107, PMID 42254059
2017 (2), 2016 (1), N01CN35160 (1), P01GM032165 (1), P01HL030086 (1), P30CA138292 (1), P50NS049060 (1), R01GM089994 (1), R01HD089474 (1), R01HL038194 (1), U01HL044315 (1), U54HD082008 (1), UL1RR024999 (1)